To the Editor,

Convergent arguments suggest that innate immunity related to neutrophils, and in particular neutrophil extracellular traps (NETs), could play a key role in response to SARS-CoV-2 infection. The neutrophil-to-lymphocyte ratio is a predictor of severity. Neutrophils are involved in the innate response to pulmonary viral infections. The production of NETs (NETosis) is increased by inflammatory mediators and activates macrophages in pulmonary alveoli. Despite these arguments, no direct evidence of the spread of NETs into circulation has been produced in the early symptomatic phase of COVID-19 and other viral infections.

We assayed myeloperoxidase-DNA (MPO-DNA) and histone-DNA complexes, two serum markers of circulating NETs, and blood cell counts in 60 consecutive ambulatory subjects attending a screening center for COVID-19 RT-PCR examination of nasopharyngeal swab samples. The study was approved by the Institutional Ethical Committee. All subjects were symptomatic with at least two very recent symptoms among fever, dry cough, and dyspnea since <1 week and most had recent contact with infected cases. They were compared to matched asymptomatic controls recruited several months before the epidemic. The sera were used after completion of biochemical testing ordered by the clinician. The remaining samples were stored in the same conditions among groups, at 20°C in the 24 hours following blood withdrawal. Histone-DNA and MPO-DNA complexes were measured in serum by the Cell Death Detection ELISA Kit (Roche Diagnostics, Sigma Aldrich), using a biotinylated antibody against histones H1, H2A, H2B, H3, and H4 or MPO and a soluble peroxidase-labeled anti-DNA monoclonal antibody, respectively, as described previously. Values were reported in 450 nm absorbance units (AU). Blood cell counts were determined in all subjects. Routine biochemical markers, including hemoglobin, bicarbonate, potassium, sodium, chloride, serum total proteins, C-reactive protein, urea nitrogen, creatinine, bilirubin, conjugated bilirubin, aspartate aminotransferase, alanine aminotransferase, lactico-dehydrogenase, gamma-glutamyl transpeptidase, alkaline phosphatase, and creatine kinase, were assayed in a Cobas 8000 Analyzer (Roche Diagnostics).

RT-PCR was positive in 34 subjects (56.6%). The mean age (±SD) in positive vs negative groups was 42 ± 17 vs 37 ± 15 (P = .3), and sex ratio (M/F) was 0.88 vs 0.73 (P = .4), respectively. We observed a higher level of MPO-DNA complexes in symptomatic subjects with positive vs negative RT-PCR (1.31 ± 0.18 vs 0.89 ± 0.21 AU, P < .001, Figure 1). The levels of MPO-DNA complexes were 3.1-fold and 2.1-fold higher in the two groups, compared to asymptomatic control subjects recruited before the epidemic (0.42 ± 0.08 AU), respectively (P < .001). Eleven symptomatic PCR-negative subjects had MPO-DNA levels higher than the 0.95 AU upper limit reported in negative symptomatic subjects. We also observed a clear increase of histone-DNA complex level in symptomatic subjects compared to controls (0.93 ± 0.25 vs 0.05 ± 0.01, P < .001) but no difference between positive and negative cases (0.94 ± 0.29 vs 0.92 ± 0.20, P = 0.9). We reported significant associations of MPO-DNA and histone-DNA complexes with markers of blood cell counts predicting severity, including neutrophil, lymphocyte, and platelet counts, and neutrophil-to-lymphocyte ratio (Figure 2) and no correlation with RT-PCR. MPO-DNA was negatively correlated with lymphocytes and platelets, while histone-DNA was positively correlated with neutrophils and neutrophil-to-lymphocyte ratio. The subjects with positive vs negative RT-PCR had decreased blood counts of leucocytes, platelets, neutrophils, and lymphocytes and increased sodium and bicarbonate. We reported no difference in other routine biochemical markers between the two symptomatic groups (Table S1) and no correlation of these biochemical parameters with blood levels of MPO-DNA and histone-DNA complexes.

**FIGURE 1** Measurement of myeloperoxidase-DNA (MPO-DNA) and histone-DNA complexes as marker of neutrophil extracellular traps (NETs) in serum of symptomatic ambulatory cases with positive or negative RT-PCR diagnosis of SARS-CoV-2 infection and 9 controls. Values were reported in 450 nm absorbance units. Bars represent mean ± SD. Data were compared by Mann-Whitney test.
FIGURE 2  A, (Top): Associations of myeloperoxidase-DNA (MPO-DNA) and histone-DNA complexes with blood counts of lymphocytes, neutrophils, and platelets. Correlations were assessed by Spearman rank correlation. The linear correlation and 95% confidence interval are represented by a line and a gray area, respectively. B, (Bottom): presumed role of NETs in SARS-CoV-2 according to pathological mechanisms reported in other viral pneumonias. Red arrows show associations documented in COVID-19, while blues arrows show mechanisms evidenced in other viral lung infections.
The increase of MPO-DNA and histone-DNA complexes in blood shows that the release of NETs is involved in the early host answer to COVID-19. The release could result from neutrophil exposure to virus particles, cytokine production, and/or response to host damage-associated molecular patterns (DAMPs) produced by infected cells, as reported in other pulmonary viral infections.3,4 Our data also show that MPO-DNA blood level is a sensitive marker of the early phase of COVID-19. All positive patients had a level dramatically higher than that observed in controls. Our data suggest to further evaluate MPO-DNA as a early marker, which could help to discriminate symptomatic patients with false-negative RT-PCR from those with negative RT-PCR related to another viral lung infection, in addition to computed tomography.7 We estimated the number of COVID-19 cases with false-negative RT-PCR to 11 among the 60 symptomatic subjects, considering the 70%-80% sensitivity of RT-PCR usually reported at very early infection step.7 This estimate is exactly the number of symptomatic negative cases who had a MPO-DNA blood level similar to that reported in symptomatic positive cases. This hypothesis is likely since these symptomatic negative cases had recent contact with infected cases. The other symptomatic patients with negative RT-PCR could have other viral infections that increase MPO-DNA to a lesser extent than COVID-19.3,5,7 This could explain the intermediate increase of MPO-DNA complexes in the symptomatic negative group, compared to controls and symptomatic positive subjects. Whether components of NETosis predict and/or contribute to evolution severity of COVID-19 remains an open question. Low lymphocyte and platelet counts and high neutrophils and neutrophil-to-lymphocyte ratio are associated with the risk of severe COVID-19, in a recent meta-analysis of 15 studies.5 The association of MPO-DNA and histone-DNA complexes with these blood cell count markers of severity (Figure 2) is in favor of this hypothesis. We suggest evaluating further whether the kinetics of blood level of NETs predict the evolution severity of COVID-19 in a larger population. NETosis participate to cytokine storm and vascular and tissue damages, including pulmonary alveoli obstruction, microthrombi with vasculitis and thromboembolic manifestations in other viral pneumonias (Figure 2).3,4,8 Very recently, a study reported 12 cases with MPO-DNA levels higher than those of controls among 50 patients hospitalized for COVID-19, and interestingly, 3 had major changes in oxygen requirement and concomitant increase of MPO-DNA levels and no increase of citrullinated histone H3-DNA.9

In conclusion, our results on a consecutive ambulatory population of COVID-19 cases suggest that blood level of MPO-DNA complexes could be a useful biomarker of the early phase of SARS-CoV-2 infection. If further studies confirm that the dramatic production of NETs is a pathological mechanism of innate immunity involved in early step of SARS-CoV-2 infection, our data could open therapeutic perspectives by targeting NET production with inhibitors already tested in other lung infectious diseases.

KEYWORDS
COVID-19, innate immunity, myeloperoxidase, neutrophil extracellular traps (NETs), neutrophils

ACKNOWLEDGMENTS
This study was registered by the Institutional Review Board of Clinical Research (DRCI) of the University Hospital of Nancy (N°2020PI087) and approved by the Ethical Committee.

CONFLICTS OF INTEREST
All authors have no conflict of interest to declare.

FUNDING INFORMATION
This work was financed by FHU ARRIMAGE and the French PIA project “Lorraine Université d’Excellence,” reference ANR-15-IDEX-04-LUE.

Jean-Louis Guéant1
Julien Fromonot2
Rosa-Maria Guéant-Rodriguez1
Patrick Lacolley3
Régis Guieu2
Véronique Regnault3

1Department INSERM UMR_S1256, Nutrition-Genetics-Environmental Risk Exposure University of Lorraine, Nancy, France
2Center for CardioVascular and Nutrition Research, INSERM, INRA and Aix-Marseille University, Marseille, France
3Department INSERM, UMR_S1116 Défaillance cardiovasculaire aigué et chronique, University of Lorraine, Nancy, France

Correspondence
Jean-Louis Guéant at the department INSERM UMR_S1256 Nutrition-Genetics-Environmental Risk Exposure, Faculty of Medicine, Avenue de la Forêt de Haye, BP 184, 54511 Vandoeuvre les Nancy, France.
Email: jean-louis.gueant@univ-lorraine.fr

ORCID
Jean-Louis Guéant https://orcid.org/0000-0002-5067-042X

REFERENCES
1. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652.
2. Zeng F, Li L, Zeng J, et al. Can we predict the severity of COVID-19 with a routine blood test? Pol Arch Intern Med. 2020;130(5):400-406. https://doi.org/10.20452/pamw.15331
3. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.
4. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18:134-147.
5. Amrane S, Tissot-Dupont H, Doudier B, et al. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: a respiratory virus snapshot. Travel Med Infect Dis. 2020;101632. https://doi.org/10.1016/j.tmaid.2020.101632. [Epub ahead of print].
Cross-sectional pilot study exploring the feasibility of a rapid SARS-CoV-2 immunization test in health and nonhealthcare workers

To the Editor,
Coronaviruses (CoV) are large, enveloped, positive-strand RNA viruses and until the first outbreak of SARS in 2002 had long been considered pathogens with low hospitalization incidence for healthy people. SARS-CoV-2 is a novel pathogenic CoV responsible for a new type of pneumonia. Initial reports placed the initial outbreak in Wuhan (China) in December 2019, and it has since spread and caused hundreds of thousands of deaths worldwide. The virus pandemic has spread extremely fast, and it is reasonable to suggest that further outbreaks may appear along the next years before effective treatments or vaccines are available in the market. Thus, in the meantime, only by achieving a better diagnostic monitoring and by understanding the interactions between the virus and host immune response will we be able to rationally manage future outbreaks.

The immune response to SARS-CoV-2 is currently under study and needs to be better characterized. However, it has been previously reported that viral infection involves activation of CD8+ cytotoxic cells, antibody-producing B cells, and innate immune response that in some patients triggers a so-called “cytokine storm”. Moreover, whether immune responses to SARS-CoV-2 generate long-term memory or whether immunized patients have long-term sterilizing immunity is still unknown.

Spain has been devastated by the COVID-19 pandemic with more than 280 000 confirmed cases, from which more than 67 000 were in Madrid, causing a huge personal, health system, and economic burden. In fact, more than 20% of infected subjects were healthcare workers.

We aimed to generate an immune response map to SARS-CoV-2 in a very specific population of a Medical School were both healthcare workers and nonhealthcare workers cohabit, and elucidate the main risk factors that can be associated with COVID-19 diagnosis in each population. With that purpose, we analyzed a population of 100 people mainly ascribed to the Medical School of San Pablo CEU University and one of its University Hospitals, HM Montepríncipe (HMM), where students perform the last 4 years of the medical degree. The population of study included 50 medical doctors from HMM that were exposed to viral loads on a daily basis (healthcare workers) and 50 researchers and teachers from the medical school that can be considered as a representative sample of the general population (nonhealthcare workers). In this study, we used the so-called “fast” IgM/IgG immunological commercial kits (REAL 2019-NCOV RAPID TEST CASSETTE) to analyze the population immunity.

Healthcare workers were recruited and classified in two subgroups depending on whether they were diagnosed or not for COVID-19 by RT-PCR (Appendix S1).

Table 1 shows that healthcare workers with a confirmed diagnosis by RT-PCR display a significant association with symptoms such as fever, cough, fatigue, dysgeusia, and anosmia. Moreover, diarrhea, even if it does not show a significant association, presents an OR of 2.65, suggesting this symptom as a novel risk factor associated with COVID-19 diagnosis. Moreover, the immunological tests demonstrate that almost 96% of the subjects diagnosed by RT-PCR were positive for IgG with an OR of 42.2. Thus, it seems there is a clear association between symptoms, RT-PCR results, and the positive results for IgG test.

Moreover, in the nonhealthcare workers population, no RT-PCR was performed for diagnosis and only 7 out of 50 subjects (14%) in the group were positive for IgG. Interestingly, these results agree with those recently published by the Spanish Ministry of Health regarding a seroprevalence study in Spanish population (n = 60 000 citizens) with different range of age, region, economic income, etc. The epidemiological study shows a seroprevalence of 11% in Madrid.

Abbreviations: CoV, Coronaviruses; COVID19, coronavirus disease 2019; HMM, Hospital Madrid Montepríncipe; IgG, Immunoglobulin G; IgM, Immunoglobulin M; RT-PCR, Reverse transcription-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VLP, Virus-like particles.